Discover why Eli Lilly's stock downturn may present new opportunities. Learn about valuation, Zepbound pricing, and 2026 ...

Use of the dual GIP/GLP-1 drug tirzepatide (Mounjaro, Zepbound) was associated with a significantly reduced risk of glaucoma ...

For 2026, the plan features significantly lower out-of-pocket costs for members who use the plan’s “narrow network” that ...

The pharmaceutical giant Eli Lilly has once again raised the bar in the highly competitive obesity treatment market. New clinical trial data for its experime ...

Eli Lilly said on Thursday its next-generation obesity drug helped patients lose an average of 28.7% of their weight in a ...

Retatrutide is an investigational triple agonist developed by Eli Lilly that targets GLP-1, GIP and glucagon receptors, and ...

The company also said earlier this week it will drop $6 billion on a new manufacturing facility in Huntsville, Alabama.

Tan France is using his experience in fashion way beyond styling. Now, the Queer Eye staple is partnering with Lilly, the makers of Zepbound, for the Changing the Thread Collection™, the first ...

The maker of Zepbound reported results from a study of retatrutide, which targets three hormones in the body and led to much more weight loss than any approved drug.

The global health organization now officially backs drugs like Wegovy for obesity management. But it might be more symbolic ...

Step aside, semaglutide—retatrutide is showing the most impressive weight loss results of any obesity drug to date.

Lilly’s closely watched retatrutide spurred as much as 29% weight loss in a Phase 3 study, a finding that is “raising the bar ...